Key Highlights
- India’s Sun Pharmaceutical Industries has reportedly proposed a $13 billion all-cash takeover of Organon (OGN)
- If finalized, this would represent Sun Pharma’s biggest-ever acquisition, with full financing from JP Morgan, MUFG, and Citi
- Organon shares skyrocketed approximately 25% Friday, building on a 20% year-to-date increase
- German firm Grünenthal and private equity group EQT have also submitted rival bids
- This represents an increase from Sun Pharma’s earlier $12 billion proposal submitted weeks ago
Shares of Organon (OGN) exploded higher by more than 25% Friday following revelations that Sun Pharmaceutical Industries of India is readying a massive $13 billion all-cash acquisition proposal for the women’s health-focused pharmaceutical company.
The Economic Times broke the story Thursday night, referencing sources with knowledge of the negotiations. OGN climbed approximately 8% in after-hours trading before accelerating gains throughout Friday’s regular session.
When the initial report surfaced, Organon carried a market capitalization of merely $2.2 billion. A $13 billion acquisition proposal would constitute an enormous premium over the company’s recent trading levels.
Should the transaction close, it would mark the largest deal in Sun Pharma’s corporate history. The complete cash financing package is reportedly arranged through JP Morgan, MUFG, and Citi.
Sun Pharma’s strategy involves integrating Organon into its current business structure. The proposal does not include issuing Sun Pharmaceutical equity to existing Organon shareholders.
This acquisition attempt isn’t Sun Pharma’s initial approach. Reports earlier this month indicated the Indian pharmaceutical leader submitted a $12 billion proposal. Friday’s reported $13 billion offer represents a billion-dollar escalation within just weeks.
Competing Offers Create Bidding War
Sun Pharma faces competition in its quest to acquire Organon. Germany-based pharmaceutical company Grünenthal and Sweden’s private equity powerhouse EQT have both reportedly submitted acquisition proposals as well.
The competitive bidding environment underscores Organon’s attractive asset base — an extensive product lineup concentrated primarily on women’s healthcare, complemented by its valuable U.S. manufacturing capabilities.
Organon became an independent entity following its separation from Merck in June 2021. The stock has experienced significant volatility since, trading down roughly 30% over the trailing twelve months despite Friday’s dramatic surge.
Heavy Trading Activity Follows News
The takeover speculation ignited intense trading volume. Approximately 5.2 million OGN shares traded hands in the early moments of Friday’s session — nearly equaling the company’s entire three-month average daily volume of 5.9 million shares within just the opening period.
Friday’s impressive 25.47% rally boosted the stock’s year-to-date return to a positive 20.25%.
OGN traded above $9.20 per share during Thursday’s extended session, representing a substantial premium to its relatively compressed $2.2 billion market cap at Thursday’s closing bell.
Neither Sun Pharma nor Organon had issued official statements confirming or denying any transaction discussions as of Friday afternoon.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
